Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models
Authors:
Open Access
- 4 May 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
The impact of first-generation covalent KRAS G12C inhibitors has been reduced due to the development of drug resistance, tolerability and challenges combining with immunotherapy. We designed olomorasib, a next-generation GDP-binding KRAS G12C inhibitor, for nanomolar potency as well as selectivity over wild-type inhibition. In both in vitro and in vivo models of KRAS G12C -mutant cancers, olomorasib reduces RAS activity and pERK levels, leading to substantial and significant tumor growth inhibition. Additionally, olomorasib combined with immune checkpoint inhibitors demonstrates greater anti-tumor activity compared to monotherapy. Furthermore, we demonstrate that olomorasib binds tightly to KRAS G12C even in the presence of clinically relevant second site mutations, a known mechanism of resistance and limitation to currently approved KRAS G12C inhibitors. These findings suggest that olomorasib could be effective for patients with KRAS G12C mutant cancers either as monotherapy or in combination with immunotherapy. Olomorasib monotherapy and combination treatments are currently being investigated clinically.Keywords
Funding Information
- Eli Lilly and Company
This publication has 38 references indexed in Scilit:
- Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung CancerJournal of Thoracic Oncology, 2023
- KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsJournal of Thoracic Oncology, 2021
- RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions2021
- Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic CancerCell Reports Medicine, 2020
- KRAS: From undruggable to a druggable Cancer TargetCancer Treatment Reviews, 2020
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2020
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid TumorsJournal of Medicinal Chemistry, 2019
- Chemical Proteomic Characterization of a Covalent KRASG12C InhibitorACS Medicinal Chemistry Letters, 2018
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010